TABLE 3.
Active clinical trials undertaken with mesenchymal stem cell-derived Extracellular vesicles in different disease treatments.
| ID (clinical trials) | EVs (cells) | Purpose | Treatment | Phase status |
|---|---|---|---|---|
| NCT04798716 | Mesenchymal stem cells (tissue not specified) | Treatment of novel coronavirus pneumonia and acute respiratory distress syndrome | Intravenously every other day on escalating dosage (2 × 109 – 4 × 109 – 8 × 109) | Not yet recruiting—Phase 1 |
| NCT05216562 | Mesenchymal stem cells (tissue not specified) | Reduce hyper-inflammation in moderate COVID-19 patients | Intravenous injection on day 1 and day 7 of a 14-day study | Phase 2—Recruiting |
| Obs: exosomes dissolved in 0.9% NaCl solution | ||||
| NCT03437759 | Umbilical cord mesenchymal stem cells | Promote healing of large and refractory macular holes | After surgery, applying 50 μg or 20 μg of exosomes in 10 μl PBS dripped, directly, into the vitreous cavity | Active, not recruiting—Early Phase 1 |
| NCT04356300 | Umbilical cord mesenchymal stem cells | Treatment of multiple organ dysfunction syndrome after surgical repair for acute type aortic dissection | 150 mg of exosomes will be injected intravenously once a day 14 times | Not yet recruiting |
| NCT04276987 | Allogenic adipose mesenchymal stem cells | Severe Novel Coronavirus Pneumonia | 2 × 108 exosomes in 3 ml aerosol inhalation for 5 days consecutively | Completed |
| NCT05261360 | Synovial fluid-derived mesenchymal stem cells | Evaluate the efficacy of exosomes in degenerative meniscal injury | Intra-articular administration—1 million cells/kg of exosomes | Recruiting—Phase 2 |
| NCT05060107 | Allogenic mesenchymal stem cells | Osteoarthritis (knee) | Intra-articular knee injection of 3–5 × 1011 particles/dose (single dose) | Not yet recruiting—Phase 1 |
| NCT05402748 | Human placenta mesenchymal stem cells | Treatment of complex anal fistula | Weekly injections for 3 consecutive weeks—dose not specified | Recruiting—Phase 1 |
| NCT04388982 | Allogenic adipose mesenchymal stem cells | Evaluated the efficacy of MSC-exos in Alzheimer’s disease patients | Nasal drip with 5, 10, and 20 μg (low, mid, and high doses, respectively) twice a week for 12 weeks | Recruiting—Phase 1 |
| NCT04313647 | Mesenchymal stem cells (tissue not specified) | Evaluated the tolerance of mesenchymal stem cell exosome aerosol inhalation (health volunteers) | 2 × 108 | 4 × 108 | 8 × 108 | 12 × 108 | 16 × 108 nanovesicles/3 ml | Completed |
| NCT03384433 | Allogenic mesenchymal stem cells (tissue not specified) | Safety and efficacy of MSC-exosomes on patients with acute ischemic stroke | Exosomes enriched with miR-124 via stereotaxis/intraparenchymal 1 month after the attack | Recruiting |
| NCT04173650 | Allogenic mesenchymal stem cells—product: AGLE-102 | Safety and efficacy of MSC-exos in the treatment of lesions in patients with epidermolysis bullosa | Six administrations of MSC-exos in 3 months in a maximum of 50 cm2 of wound | Phases 1/2 |
| NCT03608631 | Mesenchymal stem cells (tissue not specified) | Study the best dose and side effect of MSC-exos in pancreatic cancer patients | Exosomes with KrasG12D siRNA—patients received on days 1, 4, and 10 | Recruiting—Phase 1 |
| NCT04602442 | Mesenchymal stem cells (tissue not specified) | Safety and efficiency of exosomes inhalation in COVID-19 pneumonia | Inhalation of 3 ml of 0.5–2 × 1010/exosomes for 10 days | Enrolling by invitation—Phase 2 |